Lung cancer in China
China has approved lung cancer drugs not yet FDA-approved, including ivonescimab (PD-1/VEGF; three NSCLC indications, US decision due November 2026) and trastuzumab rezetecan for HER2-mutant NSCLC. Standard surgery, chemotherapy and radiotherapy are widely available at tertiary hospitals; access is through hospital oncology departments or trials.
VerifiedLast verified
Treatments available
| Treatments | Status in China | Status in US | Sources |
|---|---|---|---|
| Ivonescimab (PD-1/VEGF bispecific) | Approved in China | Not approved | NMPA (English)Akeso / HKEXnews |
| Trastuzumab rezetecan (HER2 ADC) for HER2-mutant NSCLC | Approved in China | Not approved | CancerNetwork |
| Carbon ion radiotherapy | Available | Unknown | Drugs (Springer Nature) |
Hospitals with documented programs
Informational listings from cited public sources, not recommendations.
ShanghaiZhongshan Hospital, Fudan University复旦大学附属中山医院International deptVerified
ShanghaiFudan University Shanghai Cancer Center复旦大学附属肿瘤医院International deptReported
ShanghaiShanghai Proton and Heavy Ion Center上海市质子重离子医院International deptJCIVerified
HangzhouZhejiang Cancer Hospital (Cancer Hospital of the University of Chinese Academy of Sciences)浙江省肿瘤医院（中国科学院大学附属肿瘤医院）No public intl deptVerified
BeijingBeijing United Family Hospital北京和睦家医院International deptJCIVerified
BeijingCancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center)中国医学科学院肿瘤医院No public intl deptVerified
BeijingPeking University Cancer Hospital (Beijing Cancer Hospital)北京大学肿瘤医院No public intl deptVerified
ChengduWest China Hospital, Sichuan University四川大学华西医院International deptVerified
GuangzhouSun Yat-sen University Cancer Center中山大学肿瘤防治中心International deptVerified
GuangzhouGuangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences)广东省人民医院International deptVerified
Clinical trials
914studies listed as recruiting with a site in China on ClinicalTrials.gov, as of 2026-10-26. See the list
We link trials only; enrollment decisions belong to trial teams. Since May 2026, charging patients to join clinical research is prohibited in China, as reported by AFP.
Frequently asked
Is ivonescimab available in China?
Yes. NMPA approved it in May 2024 for EGFR-mutated non-squamous NSCLC after EGFR TKI, in April 2025 for first-line PD-L1-positive NSCLC, and in August 2026 for first-line squamous NSCLC. In the US, a BLA has a PDUFA date of November 14, 2026.
[1] NMPA (English)[2] Akeso / HKEXnews[3] CancerNetworkHow many lung cancer trials recruit in China?
ClinicalTrials.gov listed 914 recruiting studies with a China site for lung cancer on 2026-10-26.
[1] ClinicalTrials.gov (…Sources
- FDA Accepts BLA for Ivonescimab Regimen in Pretreated EGFR-Mutated NSCLC
“The agency has set a Prescription Drug User Fee Act date of November 14, 2026.”
- Trastuzumab Rezetecan: First Approval
“In May 2025, it was approved by the National Medical Products Administration of China for adults with HER2-mutant unresectable or metastatic NSCLC after at least one prior systemic therapy.”
- Introduction to the Heavy Ion Centers in Wuwei and Lanzhou
“Patients from across China and countries such as Belgium, South Korea, and Australia routinely seek treatment at these centers.”
Information only. Not medical advice, diagnosis or a treatment recommendation. Talk to your doctor. In an emergency, call your local emergency number.